Literature DB >> 27041804

Lurasidone.

.   

Abstract

Entities:  

Year:  2015        PMID： 27041804      PMCID： PMC4816874          DOI： 10.18773/austprescr.2016.001

Source DB:  PubMed          Journal:  Aust Prescr        ISSN： 0312-8008


× No keyword cloud information.
  7 in total

1.  Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study.

Authors:  Leslie Citrome; Josephine Cucchiaro; Kaushik Sarma; Debra Phillips; Robert Silva; Satoru Tsuchiya; Antony Loebel
Journal:  Int Clin Psychopharmacol       Date:  2012-05       Impact factor: 1.659

2.  Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study.

Authors:  Antony Loebel; Josephine Cucchiaro; Jane Xu; Kaushik Sarma; Andrei Pikalov; John M Kane
Journal:  Schizophr Res       Date:  2013-04-11       Impact factor: 4.939

3.  Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study.

Authors:  Herbert Y Meltzer; Josephine Cucchiaro; Robert Silva; Masaaki Ogasa; Debra Phillips; Jane Xu; Amir H Kalali; Edward Schweizer; Andrei Pikalov; Antony Loebel
Journal:  Am J Psychiatry       Date:  2011-06-15       Impact factor: 18.112

4.  Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial.

Authors:  Antony Loebel; Josephine Cucchiaro; Kaushik Sarma; Lei Xu; Chuanchieh Hsu; Amir H Kalali; Andrei Pikalov; Steven G Potkin
Journal:  Schizophr Res       Date:  2013-02-13       Impact factor: 4.939

5.  Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study.

Authors:  Henry A Nasrallah; Robert Silva; Debra Phillips; Josephine Cucchiaro; Jay Hsu; Jane Xu; Antony Loebel
Journal:  J Psychiatr Res       Date:  2013-02-17       Impact factor: 4.791

6.  Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial.

Authors:  Mitsutaka Nakamura; Masaaki Ogasa; John Guarino; Debra Phillips; Joseph Severs; Josephine Cucchiaro; Antony Loebel
Journal:  J Clin Psychiatry       Date:  2009-06-02       Impact factor: 4.384

7.  Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study.

Authors:  Masaaki Ogasa; Tatsuya Kimura; Mitsutaka Nakamura; John Guarino
Journal:  Psychopharmacology (Berl)       Date:  2012-08-19       Impact factor: 4.530
  7 in total
  1 in total

1.  Inclusion complex of lurasidone hydrochloride with Sulfobutylether-β-cyclodextrin has enhanced oral bioavailability and no food effect.

Authors:  Jin Wang; Binbin Huang; Jie Dai; Guoguang Chen; Lili Ren
Journal:  Am J Transl Res       Date:  2022-03-15       Impact factor: 4.060
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.